mutations offered the fact that, as spelled out below, CLL therapy relies around the existence or absence of those mutations. The existing consensus is, in addition to clonal mutations, subclonal mutations having a variant allelic frequency starting from 5 to 10% (and for that reason below the edge of detection by traditional molecular procedures)